DiaMedica Therapeutics Inc. Q1 FY2026 earnings call

Rick Pauls starts by noting progress in 2026, poised for clinical milestones by end of 2027. Julie Krupp details preeclampsia programs: late-onset preeclampsia extension cohort near completion, expecting data update this quarter; Part 1B and Part 2 preeclampsia study groups; fetal growth restriction study enrollment expected this quarter; global Phase II study in early-onset preeclampsia with Canada approval, UK trial application expected. Scott Kallen discusses financials: cash, cash equivalents, short-term investments at $51.3M as of March 31, 2026; R&D expenses increased to $8M in Q1 2026 due to clinical trial expansion and reproductive toxicity testing, G&A expenses $2.5M.

Q: For the preeclampsia data updates that we'll get this quarter for the late onset cohort, what incremental observations should we be looking for beyond blood pressure control?

A: The expansion cohort is 12 additional patients, almost completing, giving additional clarification on blood pressure, dilation of intruder and arteries, with potential for edema and urine output improvement.

Q: What are the dating steps to start initiating enrollment in the early onset preeclampsia of study? Why is that not going to occur until later this year?

A: Need dosing data from IST study, site contracting, CRO selection, etc., with Canada enrollment expected later this year.

Q: Timelines for completing the second animal toxicology study and then ultimately re-engaging the FDA for NIMD?

A: Depends on FDA feedback, proposed rat study could take 3 - 4 months, while running phase two in Canada and expanding to UK.

Q: When could you expect to hear from the FDA on the mouse study? And is there a possibility the FDA could ask for another animal model? And how are you looking to prepare for all these different scenarios?

A: Waiting for FDA feedback, possible alternative animal models, preparing with phase two trial in Canada and UK.

Q: When could we expect to hear from the FDA on the mouse study? And is there a possibility the FDA could ask for another animal model? And how are you looking to prepare for all these different scenarios?

A: Waiting for FDA feedback, possible alternative animal models, preparing with phase two trial in Canada and UK.

Q: Should we kind of just expect to receive the number on the resample or anything else at that point that we'll be able to provide?

A: For the interim analysis, we'll be providing an update on the expected timelines to complete the enrollment.

Q: One for Scott. Appreciate your comments on forward R&D, but maybe just a little bit more color there. You said kind of modest increase. I would imagine kind of enrollment is still ticking up on an absolute number for stroke. And then can you just give us an idea you know, kind of what the magnitude of that increase you expect sequentially in stroke and then kind of the incremental cost you expect for PE through the year.

A: Modest increases in stroke enrollment driven by rates, with incremental costs for PE modest to moderate